From the Department of Intensive Care, Erasme Hospital, Free University of Brussels, Belgium (J-LV, YS); Department of Anesthesiology and Critical Care Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel (CLS); Department of Anesthesiology and Intensive Care, S. Giovanni Battista Hospital, University of Turin, Italy (VMR); Department of Anesthesiology and Intensive Care, Friedrich-Schiller-University Jena, Germany (KR); Department of Anesthesiology and Intensive Care, Vivantes-Klinikum Neukölln, Berlin, Germany (HG); Department for Intensive Care, Hospital de St, Antonio dos Capuchos, Lisbon, Portugal (RM); Department of Intensive Care, Saint-Joseph Hospital, Paris, France (JC); Department of Intensive Care, Saint-Louis Hospital, Paris, France (J-RLG); and Department of Anesthesiology and Intensive Care, Centre Hospitalier Universitaire Lariboisiere, Paris, France (DP).
Endorsed by the European Society for Intensive Care Medicine and supported by unlimited grants from Abbott, Baxter, Eli Lilly, GlaxoSmithKline, and NovoNordisk.
Dr. Carlet has received speaking fees from Wyeth and has done numerous studies with Wyeth, Chiron, GSK, Lilly, Antrics, Intrabiotics, Fujisawa, and Bayer. The remaining authors have no financial interests to disclose.